Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Multikine in the Treatment of Perianal Warts

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years of age~* Diagnosed with perianal condyloma by primary clinician~* HIV-infected, may be on or off of antiretroviral therapy~* any CD4 count will be considered appropriate for study~* Blood WBC \> 2.0x103/mm3 and absolute neutrophils count \> 500~* Blood hemoglobin \> 10.0 g/dL~* Blood platelet count \> 50x103/mm3~* Serum total bilirubin \< 6.0 mg/dL (participants taking atazanavir-based ARV regimens may have elevated total bilirubin but are generally \< 6)~* Blood aspartate aminotransferase (AST) \< 100 U/L (\<2 ULN)~* Blood alanine aminotransferase (ALT) \< 130 U/L (\<2 ULN)~* Serum creatinine \< 1.5 mg/dL~* ECOG performance status \< 3~* If a subject is of reproductive potential he/she and her/his sexual partner MUST be willing and able to utilize effective methods of contraception (e.g., birth control pill, barrier methods with spermicide - as applicable) for the duration of the study including the study follow-up period.~Exclusion Criteria:~* Anal cancer (current or history of)~* Inability to attend study visits~* Participation in any other drug study~* History of asthma~* History of organ transplantation or requiring chronic administration of immune suppressive drugs in the last 6 months~* For women, neither pregnant nor lactating~* In the opinion of the PI, the subject may not be able to tolerate the study treatment regimen

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort A (Type: EXPERIMENTAL): Cohort A participants will undergo perilesional Multikine injections (200IU) once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.
- Cohort B (Type: EXPERIMENTAL): Cohort B participants will undergo perilesional Multikine injections 400IU once daily, Monday through Friday, for 14 days, off for 14 days, then again once daily, Monday through Friday for 14 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).